Oskar Adolfsson

SA, EPFL Innovation Park Building B
Lausanne, VD 1015, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Author Correction: Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.

Author Correction: Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.

Journal: Scientific reports

Published: November 07, 2024

Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.

Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.

Journal: Scientific reports

Published: October 24, 2023

Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.

Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.

Journal: Brain communications

Published: June 12, 2023

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.

Journal: Neurobiology of disease

Published: December 20, 2022

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.

Journal: Science translational medicine

Published: February 16, 2020

Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression.

Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression.

Journal: Scientific reports

Published: July 13, 2018

Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.

Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.

Journal: Journal of Alzheimer's disease : JAD

Published: December 31, 2016

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.

Journal: Scientific reports

Published: May 20, 2016

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

Journal: Cell reports

Published: November 24, 2015

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Journal: Journal of Alzheimer's disease : JAD

Published: September 28, 2013

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy.

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy.

Journal: PloS one

Published: May 24, 2013

Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Journal: The Journal of biological chemistry

Published: August 15, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026